tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Vistagen reports Q2 EPS (54c), consensus (44c)
PremiumThe FlyVistagen reports Q2 EPS (54c), consensus (44c)
14d ago
VistaGen Completes Patient Phase in Key Clinical Trial
Premium
Company Announcements
VistaGen Completes Patient Phase in Key Clinical Trial
23d ago
VistaGen Therapeutics: Promising Prospects for Fasedienol in Social Anxiety Disorder
Premium
Ratings
VistaGen Therapeutics: Promising Prospects for Fasedienol in Social Anxiety Disorder
23d ago
Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
PremiumCompany AnnouncementsVistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
1M ago
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?
Premium
Company Announcements
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?
1M ago
VistaGen Therapeutics CFO Resignation Announced
Premium
Company Announcements
VistaGen Therapeutics CFO Resignation Announced
2M ago
VistaGen Reports Q1 2026 Financial Results and Update
PremiumCompany AnnouncementsVistaGen Reports Q1 2026 Financial Results and Update
4M ago
Vistagen reports Q1 EPS (47c), consensus (44c)
Premium
The Fly
Vistagen reports Q1 EPS (47c), consensus (44c)
4M ago
Vistagen Appoints Elissa Cote as Chief Development Officer
Premium
Company Announcements
Vistagen Appoints Elissa Cote as Chief Development Officer
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100